Imagion Biosystems Limited gives notice that, on 18 August 2020 the Company issued 21,633,200 fully paid ordinary shares (Shares) in the Company as the result of shareholders exercising their options in the Company.
Read the notice.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
February 19, 2025
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce